BioCentury | Dec 31, 2020
Politics, Policy & Law

Brexit deal gives MHRA ample room to innovate

With a thirteenth hour trade agreement putting the four-year-long Brexit ordeal in the rearview mirror, the U.K. now has the independence to cut a new path as a regulatory innovator while its scientists...
BioCentury | Dec 12, 2020
Management Tracks

Lum & Dipp’s Biospring rounds out team; plus CHOP’s Smith-Whitley joins GBT and updates from Orphazyme, Kronos, Dewpoint, Enanta and more

...Oxford; FS Investments' Lisa Detwiler; and Peter Henry, dean emeritus of NYU’s Stern School of Business.CHOP’s...
BioCentury | Nov 14, 2020
Management Tracks

COVID, Brexit await Cooke as she takes helm of EMA

Emer Cooke has succeeded Guido Rasi as EMA’s executive director, giving the regulatory agency its first new leader since 2011, handing the Irish national the task of navigating the agency through...
BioCentury | Oct 22, 2020

Data byte: who’s who among members of FDA’s COVID-19 vaccines advisory panel

The 18 members of the advisory committee that will meet Thursday to discuss FDA’s criteria for emergency use authorization of COVID-19 vaccines bring a variety of expertise and priorities to the table, from statistical chops...
BioCentury | Oct 2, 2020

Next stop IPO? Olema adds to momentum with $85M series C

Two weeks after former AstraZeneca CMO Sean Bohen took over as president and CEO, Olema has raised $85 million in a series C round led by Vivo Capital. The San Francisco company’s next financing may well...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

Two months after closing a $54 million series B round, breast cancer company Olema has followed up a flurry of executive hires with the addition of former AstraZeneca CMO Sean Bohen as president and CEO. ...
BioCentury | Aug 27, 2020
Translation in Brief

AbbVie, Harvard in $30M emerging infections partnership, Peel’s cancer therapy from CHOP and Stoke’s Dravet therapy

...chemoresistant tumor therapy based on SN22, a prodrug of irinotecan. In a Cancer Research paper published Monday, a CHOP...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting AFF4 and CDK9, components of the transcription-regulating super elongation complex, could treat diffuse midline glioma. In human diffuse midline glioma cell lines, shRNAs targeting AFF4 or CDK9 or...
BioCentury | Dec 5, 2019

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy of CAROT; and Phil Johnson, a former CSO of the Children’s Hospital of Philadelphia (CHOP...
BioCentury | Oct 31, 2019
Product Development

Amgen deal gives BeiGene dry powder to grow its own pipeline

In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed...
Items per page:
1 - 10 of 317